Capio holds 98.13 % of the voting rights of Unilabs at the end of the main acceptance period

Capio holds 98.13 % of the voting rights of Unilabs at the end of the main acceptance period
 

9 November 2007

Gothenburg, Sweden, November 9, 2007 - Capio today announced that at the end of the main offer period on November 5, 2007, Capio and the persons acting in concert with Capio hold a voting stake in Unilabs of 98.13 %.

Since the launch of the offer on October 9, 2007 until the end of the main offer period on November 5, 2007, 4:00 p.m. CET, a total of 3,091,344 Unilabs bearer shares, 5 Unilabs registered shares and a total of 3,642,844 Unilabs options on bearer shares have been tendered.

Already on October 5, Capio had announced that it had closed its purchase of the entire stake of registered and bearer shares and options of Unilabs from its majority shareholders.

The mandatory additional acceptance period runs from November 9 and ends on November 22, 2007, 4:00 p.m. CET. After the completion of the offer Capio intends to delist Unilabs from the SWX Swiss Exchange.

The offer is for CHF 57.50 per bearer share, CHF 28.75 per registered share and CHF 1.75 net in cash for each shareholder option for bearer shares. The offer price for the bearer shares represents a premium of 30.3 % over the volume weighted average price at the SWX Swiss Exchange during the 60 trading days prior to the publication of the pre-announcement on August 7, 2007.

For more information: http://www.ulbcap.info/http://www.capio.com/; www.capiodiagnostik.se;
Or please contact:
Paul Hökfelt, Capio
Mobile: +41 76 507 3333
Email: phokfelt@capio.com

Disclaimer
This document does not constitute an offer to sell or to purchase securities, nor a solicitation of an offer to sell or to purchase securities, whether in the context of the intended public tender offer in Switzerland by Capio Laboratories AB, Sweden (formerly Goldcup J 2653 AB, Sweden) (hereinafter "Capio") on the shares or option rights of Unilabs SA (hereinafter "Unilabs") or in any jurisdiction where such offer, solicitation, sale or the acceptance of such offer may be unlawful. It does also not constitute a recommendation to sell or buy shares in Capio or Unilabs. The public tender offer to the public shareholders of Unilabs and to the holders of option rights (the "Offer"), will not be made in any jurisdiction where it is contrary to applicable law or where applicable law requires Capio to modify the Offer, to submit an additional application to any authorities or other institutions, or to undertake any additional action in connection with this Offer. It is not intended to extend the Offer to any such jurisdictions. Documents related to the Offer may neither be distributed in such jurisdictions nor be sent into such jurisdictions. Persons in such jurisdictions may not use such documents to solicit purchases of securities of Unilabs.

U.S. Restrictions
The Offer will not be made, directly or indirectly, in or into the United States of America (the U.S.) or by use of the U.S. mails, or by any means or instrumentality (including, without limitation, post, facsimile transmission, telex, telephone or electronic transmission by way of the internet or otherwise) of U.S. interstate or foreign commerce or of any facility of a U.S. national securities exchange and the Offer cannot be accepted by any such use, means or instrumentality or from within the U.S. Capio will not be soliciting the tender of securities of Unilabs by any holder of such securities in the U.S. Unilabs securities will not be accepted from holders of such securities in the U.S. Any purported acceptance of the Offer that Capio or its agents believe has been made in or from the U.S. will be invalidated. Capio reserves the absolute right to reject any and all acceptances determined by them not to be in the proper form or the acceptance of which may be unlawful. Copies of the preannouncement and offer prospectus or any related offering documents must not be mailed or otherwise distributed or sent in or into the U.S. and may not be used for the purpose of soliciting the purchase of any securities of Unilabs from anyone in any jurisdiction, including the U.S., in which such solicitation is not authorized or from any person to whom it is unlawful to make such solicitation. Any person receiving the pre-announcement and|or offer prospectus (including custodians, nominees and trustees) must observe these restrictions.

Search our news

Global press contact

Sarah Rajani CFA
t: +44 20 7872 6300
sarah.rajani@apax.com

See all Press contacts

Email alerts

To keep up with our latest news Sign-up here

Capio AB

Pan-European private hospital operator